Abstract
AbstractPurpose The administration of topical tacrolimus (FK506) eye drops or ointment is used in treating corneal immune pathologies and in the prevention of the high‐risk corneal graft rejection. The purpose of this study is to develop a new well‐tolerated formulation of tacrolimus 0,06% eye drops. Procedure and the preparation are presented and discussed.Methods Tacrolimus monohydrate powder and virgin castor oil are used in this new formulation. The manufacturing process guarantees the product sterility. Analytical validation of the assay by high‐performance liquid chromatography allows precise control of the concentration of tacrolimus.Results The manufacturing and packaging of these eye drops provide good product stability. The concentration of tacrolimus 0.06% was maintained for 28 days, and no mycological or bacteriological contamination was found. Eye drop can be conserved close and exposed to the light during three months after production.Conclusion Tolerance studies are currently being carried out.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
